Ritlecitinib is a selective Janus kinase (JAK) inhibitor that primarily inhibits JAK1 and JAK3 to modulate immune responses. Its main effects include alleviating symptoms of autoimmune diseases, such as severe alopecia areata, and reducing the inflammatory response by inhibiting JAK kinase activity, which may promote hair regrowth. In addition, it is theoretically possible to use it to treat other autoimmune diseases as well. The drug has performed well in clinical trials with significant efficacy and high safety.

Ritlecitinib is a drug that is mainly used to treat alopecia areata. It is designed to help patients regain hair growth and is aimed at people suffering from alopecia areata. Its mechanism of action is mainly related to controlling the overactivity of the immune system, thereby reducing the attack on hair follicles and promoting hair regrowth.

Ritlecitinib acts primarily as a JAK inhibitor, which affects signaling pathways by inhibiting the activity of Janus kinase (JAK). This drug interferes with the transmission of specific signals in the immune system, reducing the extent to which the immune system attacks hair follicles in people with autoimmune alopecia areata. By reducing the attack on hair follicles, lituxitinib can promote hair growth and slow hair loss.

Ritectinib has been shown to have a positive impact in clinical trials in the treatment of alopecia areata patients. Studies have shown that the use of ritekitinib significantly improves hair regrowth and growth in patients with alopecia areata, thereby improving the quality of life of patients. This medication not only promotes new hair growth, but also slows or stops hair loss, providing patients with the possibility of long-term improvement and management of alopecia areata.